
ISPC Valuation
iSpecimen Inc
- Overview
- Forecast
- Valuation
- Earnings
ISPC Relative Valuation
ISPC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ISPC is overvalued; if below, it's undervalued.
Historical Valuation
iSpecimen Inc (ISPC) is now in the Overvalued zone, suggesting that its current forward PS ratio of 0.37 is considered Overvalued compared with the five-year average of -14.74. The fair price of iSpecimen Inc (ISPC) is between 0.56 to 0.99 according to relative valuation methord. Compared to the current price of 1.18 USD , iSpecimen Inc is Overvalued By 19.62%.
Relative Value
Fair Zone
0.56-0.99
Current Price:1.18
19.62%
Overvalued
-0.07
PE
1Y
3Y
5Y
Trailing
Forward
-0.91
EV/EBITDA
iSpecimen Inc. (ISPC) has a current EV/EBITDA of -0.91. The 5-year average EV/EBITDA is -1.55. The thresholds are as follows: Strongly Undervalued below -9.30, Undervalued between -9.30 and -5.43, Fairly Valued between 2.32 and -5.43, Overvalued between 2.32 and 6.20, and Strongly Overvalued above 6.20. The current Forward EV/EBITDA of -0.91 falls within the Historic Trend Line -Fairly Valued range.
-0.63
EV/EBIT
iSpecimen Inc. (ISPC) has a current EV/EBIT of -0.63. The 5-year average EV/EBIT is -1.21. The thresholds are as follows: Strongly Undervalued below -7.17, Undervalued between -7.17 and -4.19, Fairly Valued between 1.78 and -4.19, Overvalued between 1.78 and 4.76, and Strongly Overvalued above 4.76. The current Forward EV/EBIT of -0.63 falls within the Historic Trend Line -Fairly Valued range.
0.53
PS
iSpecimen Inc. (ISPC) has a current PS of 0.53. The 5-year average PS is 1.53. The thresholds are as follows: Strongly Undervalued below -2.19, Undervalued between -2.19 and -0.33, Fairly Valued between 3.39 and -0.33, Overvalued between 3.39 and 5.25, and Strongly Overvalued above 5.25. The current Forward PS of 0.53 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
iSpecimen Inc. (ISPC) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
-0.55
P/FCF
iSpecimen Inc. (ISPC) has a current P/FCF of -0.55. The 5-year average P/FCF is -1.69. The thresholds are as follows: Strongly Undervalued below -6.06, Undervalued between -6.06 and -3.88, Fairly Valued between 0.50 and -3.88, Overvalued between 0.50 and 2.69, and Strongly Overvalued above 2.69. The current Forward P/FCF of -0.55 falls within the Historic Trend Line -Fairly Valued range.
iSpecimen Inc (ISPC) has a current Price-to-Book (P/B) ratio of 1.77. Compared to its 3-year average P/B ratio of 0.70 , the current P/B ratio is approximately 153.04% higher. Relative to its 5-year average P/B ratio of 1.23, the current P/B ratio is about 44.13% higher. iSpecimen Inc (ISPC) has a Forward Free Cash Flow (FCF) yield of approximately -158.07%. Compared to its 3-year average FCF yield of -137.65%, the current FCF yield is approximately 14.84% lower. Relative to its 5-year average FCF yield of -105.58% , the current FCF yield is about 49.72% lower.
4.74
P/B
Median3y
0.70
Median5y
1.23
-91.61
FCF Yield
Median3y
-137.65
Median5y
-105.58
Competitors Valuation Multiple
The average P/S ratio for ISPC's competitors is 0.26, providing a benchmark for relative valuation. iSpecimen Inc Corp (ISPC) exhibits a P/S ratio of 0.53, which is 103.88% above the industry average. Given its robust revenue growth of -75.10%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ISPC decreased by 78.33% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -73.65 to -146.85.
The secondary factor is the Revenue Growth, contributed -75.10%to the performance.
Overall, the performance of ISPC in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch

SXTP
60 Degrees Pharmaceuticals Inc
1.300
USD
-1.52%

ADTX
Aditxt Inc
1.060
USD
+3.92%

APVO
Aptevo Therapeutics Inc
2.070
USD
+3.50%

BJDX
Bluejay Diagnostics Inc
1.390
USD
+2.21%

FRGT
Freight Technologies Inc
1.350
USD
-1.10%

VLCN
Volcon Inc
10.610
USD
-15.80%

ACON
Aclarion Inc
7.278
USD
-0.55%

CYCC
Cyclacel Pharmaceuticals Inc
7.520
USD
-5.41%

NAOV
Nanovibronix Inc
6.350
USD
+8.36%
FAQ

Is iSpecimen Inc (ISPC) currently overvalued or undervalued?
iSpecimen Inc (ISPC) is now in the Overvalued zone, suggesting that its current forward PS ratio of 0.37 is considered Overvalued compared with the five-year average of -14.74. The fair price of iSpecimen Inc (ISPC) is between 0.56 to 0.99 according to relative valuation methord. Compared to the current price of 1.18 USD , iSpecimen Inc is Overvalued By 19.62% .

What is iSpecimen Inc (ISPC) fair value?

How does ISPC's valuation metrics compare to the industry average?

What is the current P/B ratio for iSpecimen Inc (ISPC) as of Aug 19 2025?

What is the current FCF Yield for iSpecimen Inc (ISPC) as of Aug 19 2025?

What is the current Forward P/E ratio for iSpecimen Inc (ISPC) as of Aug 19 2025?
